Retatrutide Dose Conversion: Weekly to Daily Explained for Women

What "Weekly to Daily Conversion" Actually Means for Retatrutide

Retatrutide is dosed once weekly by subcutaneous injection, and no licensed daily formulation exists. The phrase "weekly to daily conversion" comes up in two practical contexts: compounding pharmacy labeling (which sometimes lists a per-day concentration), and patient self-tracking in apps that log a daily mg intake. The math is simple division.

The conversion formula:

Daily equivalent (mg/day) = Weekly dose (mg) ÷ 7

At the 12 mg/week maintenance dose used in the phase 2 NEJM trial, the daily equivalent is approximately 1.71 mg/day. At the 8 mg/week dose, it is approximately 1.14 mg/day. These are pharmacokinetic averages, not separate dosing regimens.

Retatrutide's half-life in human studies is approximately six days, which means a single weekly injection produces a relatively stable steady-state plasma concentration by week four to six of dosing. This long half-life is precisely why daily dosing is not necessary and why the conversion number is a tracking fiction rather than a clinical instruction.

The Phase 2 Titration Schedule: What the Trial Data Show

The NEJM phase 2 randomized controlled trial (Jastreboff et al., 2023) enrolled 338 adults with obesity (BMI ≥ 30 or BMI ≥ 27 with at least one weight-related condition) across multiple dose arms. Understanding the titration schedule matters because jumping to the maintenance dose too quickly is the most common reason women stop GLP-1 or triple-agonist therapy due to nausea.

The Titration Steps Used in the Phase 2 Trial

The highest-dose arm (targeting 12 mg once weekly) followed this stepped schedule:

| Week | Dose (once weekly) | Daily equivalent | |------|-------------------|-----------------| | 1-4 | 2 mg | 0.29 mg/day | | 5-8 | 4 mg | 0.57 mg/day | | 9-12 | 8 mg | 1.14 mg/day | | 13-16 | 12 mg | 1.71 mg/day | | 17-48 | 12 mg (maintenance) | 1.71 mg/day |

Participants spent 12 weeks titrating before reaching full maintenance, giving the GI tract time to adapt. The trial reported that nausea occurred in 45% of the 12 mg group, but severe nausea led to discontinuation in fewer than 5% of participants. Slow titration was central to tolerability.

Why Some Compounding Protocols Use a Slower Ramp

Compounding pharmacies working with prescribers sometimes extend the titration to 20 or 24 weeks before reaching 12 mg, particularly for women with a history of severe GI reactions to semaglutide or tirzepatide. This is clinically defensible given that no harm signal has been associated with slower titration in the GLP-1 and GIP/GLP-1 literature. The tradeoff is a delayed onset of maximum weight loss.

A clinically useful way to think about retatrutide titration for women is the "GI-first, efficacy-second" framework: prioritize reaching a dose your GI tract can tolerate before chasing the weight loss numbers. For women with PCOS or perimenopause-related metabolic changes, the hormonal context changes the side-effect experience at each step, as described below.

Sex-Specific Pharmacokinetics and Why Your Dose May Feel Different

Women metabolize GLP-1 class drugs differently from men in several documented ways, and the same pattern is expected with retatrutide based on mechanistic overlap.

Body Composition and Volume of Distribution

Women carry a higher percentage of body fat relative to lean mass than men at equivalent BMI. This affects the volume of distribution for lipophilic drugs. While retatrutide's full sex-stratified PK data are not yet published from phase 3 trials, the semaglutide prescribing information documents that women have approximately 17% higher exposure (AUC) than men after weight adjustment, a pattern driven by lean body mass differences rather than sex hormones alone. Retatrutide may follow a similar pattern.

Clinical implication: If you are a smaller woman (under 65 kg), you may reach effective GLP-1 receptor saturation at a lower dose than the 12 mg maintenance target. Dose capping at 8 mg is reasonable to discuss with your prescriber if you are losing weight steadily and tolerating therapy well.

The Menstrual Cycle and GI Side Effects

GI motility slows in the luteal phase (days 14-28 of a typical 28-day cycle) due to the inhibitory effect of progesterone on smooth muscle. Retatrutide further slows gastric emptying through its GLP-1 component. This means nausea, bloating, and constipation may be noticeably worse in the week before your period, particularly during the first four to eight weeks at each new dose step.

A practical approach: if you are mid-titration and your injection day falls consistently in your luteal phase, consider asking your prescriber whether shifting injection day by two to three days is feasible to see whether GI timing improves. This has not been studied in a retatrutide-specific RCT, but it is consistent with what is known about progesterone and GI motility from the broader gastroenterology literature.

Perimenopause: The Estrogen Drop Changes Everything

In perimenopause, estrogen levels fluctuate unpredictably before declining. Estrogen has a protective effect on gut barrier function and influences gastric emptying. As estrogen falls, visceral fat accumulates preferentially, which is exactly the fat depot that retatrutide's glucagon receptor agonism targets. This makes retatrutide mechanistically attractive for perimenopausal weight gain, but the same gut changes that come with lower estrogen may amplify GI side effects during titration.

Women in perimenopause who are starting retatrutide may benefit from a 20-week rather than 16-week titration schedule, spending four to six weeks at each dose step instead of four. This is particularly relevant if you are also on menopausal hormone therapy (MHT), since oral estrogen affects clotting and metabolic parameters in ways that interact with obesity pharmacotherapy, though no direct retatrutide-MHT interaction data exist yet.

Efficacy Data Specific to Women

The NEJM phase 2 trial reported that participants receiving 12 mg retatrutide once weekly lost a mean of 24.2% of body weight at 48 weeks in the highest-dose cohort. The trial was not powered for sex-stratified efficacy analysis, and disaggregated weight loss data by sex have not been published for retatrutide as of mid-2025. This is a genuine evidence gap.

By comparison, the SURMOUNT-1 trial of tirzepatide showed women lost slightly more weight than men at equivalent doses, which is consistent with the higher drug exposure seen in women. If retatrutide follows the same pattern, women may reach meaningful weight loss at a lower maintenance dose than 12 mg, though this remains extrapolated rather than directly studied.

The FDA has required sex-disaggregated reporting in NDA submissions since 2014, meaning retatrutide's phase 3 submission will need to include this data. That data is not yet publicly available.

Retatrutide and PCOS: What the Glucagon Receptor Adds

Polycystic ovary syndrome (PCOS) affects an estimated 8-13% of women of reproductive age worldwide, and insulin resistance is central to its metabolic phenotype. GLP-1 receptor agonists have established evidence in PCOS for improving insulin sensitivity, reducing androgen levels, and restoring menstrual regularity. Retatrutide adds GIP and glucagon receptor agonism to this GLP-1 base.

Why the GCGR Component Matters in PCOS

The glucagon receptor component in retatrutide increases energy expenditure and promotes hepatic fat reduction. Women with PCOS have a disproportionately high rate of non-alcoholic fatty liver disease (NAFLD), now termed metabolic dysfunction-associated steatotic liver disease (MASLD). A 2023 meta-analysis found that GLP-1 receptor agonists reduced liver fat by a mean of 4.4% on MRI in NAFLD populations. Retatrutide's GCGR activity may add additional hepatic benefit, though PCOS-specific liver data for retatrutide do not yet exist.

Menstrual Cycle Restoration

Significant weight loss in women with PCOS (10% or more of body weight) is associated with resumption of ovulatory cycles. This means that as retatrutide produces weight loss, ovulation may resume in women who were previously anovulatory, including those who were not using contraception because they believed they were infertile. This is not hypothetical. The same pattern was documented with semaglutide in PCOS patients. See the pregnancy section below for why this matters.

Pregnancy, Lactation, and Contraception

Retatrutide is contraindicated in pregnancy. No exceptions.

Animal reproductive toxicology data submitted with the phase 2 program showed dose-dependent fetal harm in rodent studies at exposures relevant to human clinical doses. While no controlled human pregnancy data exist, the mechanism of action (caloric restriction at a cellular signaling level, reduced gastric emptying, potential effects on fetal glucagon-GLP-1 axis development) gives no basis for considering retatrutide safe in pregnancy.

Before You Start: Contraception Requirements

Because retatrutide may restore ovulation in women with PCOS or weight-related anovulation, you must use reliable contraception from the day you take your first dose. "Reliable" means a method with a typical-use failure rate below 5% per year: combined oral contraceptive pills, IUDs (hormonal or copper), implant, or barrier plus hormonal method.

Oral contraceptives may have slightly reduced absorption during the first several weeks of retatrutide use due to delayed gastric emptying, a concern documented with oral semaglutide and the Ozempic label. An IUD or implant avoids this interaction entirely.

If You Plan to Conceive

Discontinue retatrutide at least four weeks before your first unprotected cycle. Retatrutide's half-life of approximately six days means roughly five half-lives (approximately 30 days) are needed to clear the drug from your system. This four-week washout is a conservative minimum, not a guarantee of zero exposure.

There is no established safe re-start point postpartum if you are breastfeeding. Retatrutide's lactation transfer has not been studied in humans. Given its molecular weight and protein-binding properties, some transfer into breast milk is expected, though GI degradation in the infant would likely limit systemic exposure. Given the absence of safety data, ACOG's general principle of avoiding drugs without established lactation safety data in breastfeeding women applies here. Do not use retatrutide while breastfeeding.

Postpartum Women

Postpartum weight retention is a recognized clinical problem, affecting a mean of 3-5 kg retained at 12 months after delivery in observational studies. Retatrutide may eventually be a tool for postpartum weight management, but not until breastfeeding is complete and adequate time has passed. No postpartum-specific retatrutide data exist.

Who This Drug May Be Right For (and Who Should Wait)

Potentially Appropriate Life Stages and Conditions

• Women with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with PCOS, type 2 diabetes, hypertension, or dyslipidemia who have not met weight goals with semaglutide or tirzepatide
• Perimenopausal or postmenopausal women with visceral fat accumulation and metabolic syndrome, where the GCGR component may address hepatic fat more aggressively than dual agonists
• Women with MASLD and obesity who need liver fat reduction alongside weight loss
• Women who tolerated prior GLP-1 therapy but did not achieve sufficient weight loss

Women Who Should Not Use Retatrutide Now

• Pregnant women or those actively trying to conceive
• Breastfeeding women
• Women with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome (consistent with the GLP-1 class thyroid C-cell risk signal)
• Women with active pancreatitis or a history of severe pancreatitis
• Women with end-stage renal disease (PK data insufficient)

The trial excluded women with type 1 diabetes, recent cardiovascular events, and severe GI disease. These exclusion criteria are reasonable caution zones until phase 3 data clarify safety.

Practical Dosing Guidance: Converting Your Weekly Prescription to Daily Tracking Numbers

If you are using a health-tracking app or your compounding pharmacy labels your solution in mg/mL without specifying the weekly total, use this reference table.

| Weekly dose | Daily equivalent | Approximate weekly injection volume (if 10 mg/mL solution) | |-------------|-----------------|-----------------------------------------------------------| | 2 mg | 0.29 mg/day | 0.20 mL | | 4 mg | 0.57 mg/day | 0.40 mL | | 8 mg | 1.14 mg/day | 0.80 mL | | 12 mg | 1.71 mg/day | 1.20 mL |

Important: Compounding concentrations vary. Always confirm mg/mL with your pharmacy before drawing your dose. A 5 mg/mL solution requires twice the volume for the same dose. Dosing errors with compounded GLP-1 class drugs have been documented by the FDA and result from concentration confusion, not from the drug itself.

Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate sites weekly. Store reconstituted peptide as your pharmacy instructs, typically at 2-8°C for up to 28 days.

Thyroid Monitoring: A Sex-Specific Note

Women develop thyroid disease at five to eight times the rate of men. Thyroid dysfunction is common in PCOS and in the perimenopause transition. GLP-1 receptor agonists carry a class warning for thyroid C-cell tumors based on rodent carcinogenicity data. This has not been confirmed in humans in large observational studies of semaglutide and liraglutide, but the signal exists.

Before starting retatrutide, your prescriber should review your thyroid history. If you have Hashimoto's thyroiditis or subclinical hypothyroidism, document your baseline TSH. Unexplained neck swelling, dysphagia, or hoarseness during therapy should prompt prompt evaluation. This is not unique to retatrutide but is more clinically relevant for women given baseline thyroid disease prevalence.

The Evidence Gap: What We Don't Know Yet for Women

Honesty about data gaps is part of responsible prescribing information.

• No sex-disaggregated weight loss data from the retatrutide phase 2 trial have been published as of mid-2025.
• No pharmacokinetic studies in women across the menstrual cycle, in perimenopause, or on MHT have been published.
• No PCOS-specific retatrutide trials exist.
• No lactation transfer data exist.
• The phase 3 trials (TRIUMPH program) are ongoing. Until those results are published and reviewed, prescribing decisions are extrapolated from phase 2 data and class-level evidence from GLP-1 and GIP/GLP-1 agonists.

If you are prescribed retatrutide off-label or through a compounding pharmacy before FDA approval, ask your prescriber to document the clinical rationale in your chart and to review phase 3 results as they emerge.